Yasin Keshvargar
Lawyers
Filters
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2028, 2030, 2032, 2035, 2055 and 2065
GH Research $150 million follow-on offering
We advised GH Research on the offering of shares
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
Precigen $79 million preferred stock and warrants offering
We advised Precigen on the private placement
Ormat Technologies $282 million secondary offering
The stock is listed on the NYSE and Tel Aviv Stock Exchange
Sabre $800 million exchange offer and $775 million term loan exchange
We are advising Sabre on the exchange offers
Enviva emerges from chapter 11
We advised an ad hoc group of creditors in connection with Enviva’s chapter 11 proceedings
Spirit Airlines prearranged chapter 11 filing
We are advising Spirit Airlines in connection with entry into an RSA and negotiation of a prearranged chapter 11 plan
Molecular Partners $20 million follow-on offering
The ADSs are listed on the Nasdaq Global Select Market
Inventiva private placement of up to €348 million
The offering includes ordinary shares, pre-funded warrants and warrants